INTRODUCTION {#s1}
============

The male-to-female sex ratio at birth is very constant across world populations, ranging between 1.02 and 1.08 (102--108 male to 100 female live births), with an average of 1.06 for populations of European descent ([@DDS304C1]--[@DDS304C3]). The sex ratio at birth is mainly determined by factors influencing the primary sex ratio, which is the sex ratio at conception, and those influencing the survival of the embryo ([@DDS304C4]). Frequently reported primary sex ratio-determining factors include motility and survival time of X-bearing and Y-bearing sperm. A proportion of prenatal mortality can be attributable to immunological interaction between mother and embryo ([@DDS304C4]). Interestingly, more males are being born in spite of the fact that there is higher mortality of males than females during intrauterine life ([@DDS304C4],[@DDS304C5]). In addition, the sex ratio is considered to be affected by numerous other biological (endogenous) and environmental (exogenous) factors, albeit their influence is generally thought to be of a small effect ([@DDS304C1],[@DDS304C6]). These factors include gonadotropins and/or testosterone concentration at the time of conception, ovulation induction, parental age, parity, birth order, coital rates, infertility, parental illness, maternal malnutrition, smoking, exposure to certain chemicals, stress, war, socioeconomic status and many others ([@DDS304C1],[@DDS304C6]--[@DDS304C8]). The variation in sex ratio was also observed in many animal and plant species ([@DDS304C9]). Studies of parasitoid wasps, particularly *Nasonia vitropennis*, identified several quantitative trait loci (QTL) associated with the sex ratio, pointing to a genetic contribution ([@DDS304C9]). In addition, many authors suggest that the human sex ratio also has a heritable component. Paternal effects have been proposed to play a role in the sex ratio, for example, men with more brothers tend to have more sons whereas men with more sisters tend to have more daughters ([@DDS304C5],[@DDS304C10],[@DDS304C11]). Based on population genetics modelling, Gellatly *et al*. ([@DDS304C11]) suggested that the sex ratio is determined by common inheritance of polymorphic autosomal genes that exert their effect through the male reproductive system. Another study of reproductive fitness in the Hutterite population suggested that genetic variants, both autosomal and X-linked, influence natural fertility in humans ([@DDS304C12]). Research of human births in two-child families observed that sexes of offspring do not follow a binomial model of inheritance where probability of having a boy equals probability of having a girl ([@DDS304C13]). This study also pointed to the lack of independence among sexes of children of the same parents ([@DDS304C13]). A couple of possible genetic mechanisms underlying this observation such as Y- and X-linked immunological incompatibilities between mother and embryo have been proposed ([@DDS304C13],[@DDS304C14]).

In the present study, we test whether common variant genetic effects partly underlie the observed male-to-female sex ratio at birth. To address this, we investigate the presence of autosomal and chromosome X variant differences between men and women across 114 863 individuals through large-scale genome-wide association study (GWAS) meta-analysis. We also conduct a forward-time simulation study to assess the probability of observing significant allele frequency differences at autosomal markers between men and women. Our study has high power to detect loci with modest to small effect sizes.

RESULTS {#s2}
=======

GWAS meta-analysis results {#s2a}
--------------------------

Initial meta-analysis results pointed to an excess of associations compared with the null distribution (Fig. [1](#DDS304F1){ref-type="fig"}A). We examined all genome-wide significant SNPs with effective sample size \>10 000 to check for false positives due to genotyping error or other artefacts. We investigated three main diagnostic metrics: poor cluster plots in men or women ([Supplementary Material, Fig. S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1)), sequence similarity on chromosome Y and exact Hardy--Weinberg equilibrium (HWE), *P* \< 1.0 × 10^−6^ for men or women. Autosomal SNPs that lie in genomic regions that have sequence similarity on the Y chromosome may be incorrectly genotyped/called in men, but not in women, which may give rise to false-positive associations. This can be traced through several quality control (QC) checks in men: excess of heterozygosity, deviation from HWE and poor cluster plots in men and not in women. Some/all of these factors were observed for SNPs designated for exclusion from follow-up (all with highly significant association *P*-values). We excluded SNPs from the pseudoautosomal chromosome X boundary regions (within 55 kb on the short arm of chromosome X and 115 kb on the long arm that lie next to the non-pseudoautosomal regions) to guard against genotyping error in men (for example, caused by the presence of truncated copies of genes and/or mappings to multiple places across the genome). After exclusion of all poorly genotyped/called SNPs, we detect a single genome-wide significant association at a non-pseudoautosomal chromosome X variant (rs12689384, *P* = 2.66 × 10^−13^), which is an intronic variant within *RBMX2*. As this SNP was imputed in all studies driving the association, we checked cluster plots of all directly typed variants 500 kb upstream and downstream of the associated SNP in all studies, excluded SNPs with poor clustering, re-imputed the region and re-run the meta-analysis. The significance of rs12689384 dropped by five orders of magnitude (allele G, OR = 1.18, 95% CI \[1.11--1.25\], *P* = 3.27 × 10^−8^) but remained nominally genome-wide significant. However, there are several factors that reduce the credibility of this finding. First, 12 studies in total contributed summary statistics for this variant (for a total of 33 259 individuals), out of which six WTCCC1 studies drive the association ([Supplementary Material, Table S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1)). This SNP is imputed in all WTCCC1 studies. Secondly, as shown in the regional association plot ([Supplementary Material, Fig. S2](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1)), this SNP lacks support for association from neighbouring variants. The next most statistically strong association in the region is modest (*P* = 1.99 × 10^−4^) and observed at an SNP (rs2294956) which is in perfect linkage disequilibrium with rs12689384 (*r*^2^= 1, D' = 1) based on HapMap CEU, on which imputation was based. This second SNP (rs2294956) is also imputed in the WTCCC1 studies, but in fact the meta-analysis includes data from over twice the sample size (31 studies, 67 162 individuals, [Supplementary Material, Table S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1)). All studies contributing directly typed data for this variant (46 066 individuals with directly typed data) show no evidence for association, indicating that the signal observed at the imputed variant may be an artefact. We have therefore not considered this single associated SNP any further. Figure 1.QQ plots for 2 623 828 directly genotyped and imputed SNPs: (**A**) for all examined SNPs; (**B**) after exclusion of poorly genotyped/called SNPs.

The distribution of association *P*-values after meta-analysis QC was consistent with the null (Fig. [1](#DDS304F1){ref-type="fig"}B). Our study has 80% power to detect OR of 1.13 (at *α* = 5 × 10^−8^) for SNPs with minor allele frequency (MAF) \>5%, assuming an additive model. We did not further examine SNPs with *P*-values above the genome-wide significance threshold since our study had sufficient power to detect associations of loci with small-to-modest effect sizes.

Simulation study results {#s2b}
------------------------

Association analysis of 1 337 699 autosomal common and 135 988 autosomal low-frequency variants in the simulated case--control set matching the empirical study did not identify any differences in allele frequencies between men and women (*α* = 5 × 10^−8^). Quantile--quantile (QQ) plots for simulated common and low-frequency variants are shown in [Supplementary Material, Figure S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1).

DISCUSSION {#s3}
==========

This large-scale investigation across 114 863 individuals identified no detectable contribution from common genetic variants to the observed skew in sex ratio at birth. This study combined the data from 51 cohorts and has excellent power to detect small-to-modest effect sizes at common loci. The sample sizes contributing to the analysis of chromosome X SNPs were lower due to limited overlap of directly typed SNPs across platforms (in the absence of imputed data across all studies). However, power remains high at over 80% to detect small-to-modest effect sizes. From the phenotypic aspect, sex is a well-characterized trait representing an additional strength of this study, which is unlikely to suffer from phenotype misclassification.

Our results, within the power constraints of our study, indicate that sex-specific selection against particular autosomal genetic variants is not a plausible explanation for the observed male-to-female sex ratio at birth and argue against the hypothesis that incompatible genotypes at common variants between the autosomes and sex chromosomes could lead to miscarriage, thus generating sex-specific genetic differences. We performed forward-time simulations of 1.3 million independent autosomal, common, neutral loci, conditioning on the male-to-female sex ratio at birth, in a cohort matching the original study sample. The lack of any significant allele frequency differences between men and women was in keeping with the findings of the GWAS meta-analysis for autosomal SNPs. We also tested the effects of low-frequency variants in the simulated data, and found no evidence for association with the observed sex ratio at birth. However, we cannot rule out the effects of rare, structural or chromosome Y variants since these were not analysed in our study.

Sex chromosome loci may be relevant for the sex ratio determination due to their expression in the reproductive system, their role in spermatogenesis, sperm morphogenesis and movement and male--female fertility in general ([@DDS304C15],[@DDS304C16]). Therefore, we performed a comprehensive chromosome X analysis involving two main chromosome X regions: pseudoautosomal and non-pseudoautosomal. There are two pseudoautosomal regions (PAR1 and PAR2), which are homologous on X and Y chromosomes, and for which men and women carry two alleles per SNP, whereas for the non-pseudoautosomal region men carry only one allele per SNP. We investigated allele frequency differences between men and women in both chromosome X regions and we observed the association of one non-pseudoautosomal SNP (rs12689384) just below the genome-wide significance level. For various reasons expanded in the Results section, we believe that this variant may be an imputation artefact and have thus not taken it forward to further studies.

The investigated dataset consisted of more women (61 094) than men (53 769). Our meta-analysis incorporated summary statistics deriving from 51 collaborating studies and the vast majority of these studies (36 studies) are population based. The main difference in the sex ratio is driven by these population based studies and the reasons for having fewer men can be heterogeneous and study specific. Most likely the main reasons are the generally recognized lower male response to take part in epidemiological population-based studies ([@DDS304C17]) and/or sex differences in longevity where women have a higher expected lifespan ([@DDS304C18]). Fifteen of the 51 contributing studies are disease- rather than population-based and the sex ratio in these studies approximately corresponds to the disease sex ratio in the population. We were driven by the rationale that the sex ratio at birth is constant throughout time and across all world populations, meaning that common variants are more likely to underlie the observed sex ratio at birth. Therefore, in the case of a higher male death rate, we would still have enough power to detect common variant differences due to a very large sample set. However, there are scenarios where this sampling difference between men and women might cause bias, for example there may be a genetic variant that is influencing both the sex ratio and longevity in men. In that case, higher male death rate would cause the removal of this specific genetic variant, thus masking the signal.

Our results have important implications for genetic association study design, for example regarding the selection of control sets for sex-biased traits such as prostate cancer in men or anorexia nervosa in women. The use of single-sex controls for sex-specific diseases generally decreases the sample size and power of a study. Our findings demonstrate that mixed sex controls can be used as an appropriate set in studies of sex-specific traits, when focusing on common loci. As one additional implication for genetic association study analyses, our study stresses the importance of careful pre- and post-analysis QC. QQ plots of our initial meta-analysis results showed high deviation from the null, yet, after QC we observe no inflation of signal. A robust and thorough QC pipeline is necessary to verify any positive association signals, especially in meta-analyses where many studies contribute data that were genotyped (and phenotyped) in many different settings.

We conclude that common genetic variants do not play a role in defining male-to-female sex ratio at birth. In this large-scale meta-analysis of ∼115 000 individuals, we found no allele frequency differences at common loci between men and women. Simulated data of autosomal neutral variants support these findings. Our results can be useful in informing GWAS study design, especially when using mixed controls for sex-biased traits.

MATERIALS AND METHODS {#s4}
=====================

Study samples {#s4a}
-------------

We conducted genome-wide meta-analysis across 51 studies, comprising overall 114 863 individuals (61 094 women and 53 769 men) of European ancestry. The characteristics of samples from contributing studies are presented in [Supplementary Material, Table S2](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1).

Ethics statement {#s4b}
----------------

Each study obtained ethical approval from their respective research ethics committee and all participants gave signed informed consent in accordance with the Declaration of Helsinki.

Genotyping, imputation and QC {#s4c}
-----------------------------

All samples were genotyped using commercially available Illumina (Illumina, Inc., San Diego, CA, USA) or Affymetrix (Affymetrix, Inc., Santa Clara, CA, USA) platforms. Imputation of missing genotypes was based on HapMap Phase II genotypes for the European population (CEU). QC of directly typed and imputed variants was conducted separately in each study. Study-specific information on genotyping platforms, imputation methods and QC metrics is presented in [Supplementary Material, Table S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1). QC checks included tests for relatedness among samples within individual studies.

Genome-wide association analysis of autosomal variants {#s4d}
------------------------------------------------------

Case--control association analysis of autosomal SNPs was conducted under the additive model, for directly typed and imputed variants, within each study. Women were coded as cases and men as controls. Association analyses of imputed variants took genotype uncertainty into account, with the exception of the QIMR study which conducted analysis on best-guess genotypes. Where necessary, the first three genotype-based principal components were used as covariates. Studies with related individuals additionally adjusted analyses for family relatedness using linear mixed models. Study-specific association analysis software is presented in [Supplementary Material, Table S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1).

Chromosome X analysis {#s4e}
---------------------

Each contributing study performed two separate chromosome X analyses, including pseudoautosomal and non-pseudoautosomal regions. Association analyses were performed, as per autosomes, under the additive model. Overall, 42 studies performed analysis of pseudoautosomal region, 11 of these imputed data using HapMap Phase II, all others used directly typed variants only. For non-pseudoautosomal region, 46 studies performed association analysis, 12 of these used HapMap Phase II imputed data whereas others used directly typed variants only. Study-specific chromosome X imputation/association analysis software is presented in [Supplementary Material, Table S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1).

GWAS meta-analysis {#s4f}
------------------

We performed fixed and random effects meta-analysis to synthesize summary statistics results across contributing studies to identify autosomal and chromosome X common SNP differences between men and women. For meta-analysis purposes, we used GWAMA ([@DDS304C19]). Prior to meta-analysis, we excluded SNPs with MAF lower than 0.05 and SNPs with low imputation accuracy scores. Specifically, we used a cut-off of rsq_hat \< 0.3 for genotypes imputed with MACH ([@DDS304C20]), BEAGLE ([@DDS304C21]) and PLINK ([@DDS304C22]) software and a cut-off of proper info score \<0.5 for IMPUTE ([@DDS304C23]) software. Overall, 2 623 828 directly genotyped and imputed SNPs passed QC criteria and were included in the meta-analysis. The genomic control (GC) inflation factor (lambda) was calculated and applied to correct the results for each study separately prior to the meta-analysis. The meta-analysis results were also corrected for overall lambda GC. The average GC inflation factor across studies was 1.005 for directly genotyped SNPs, 0.97 for imputed SNPs and 1.007 overall, suggesting little population stratification. To determine the effective number of individuals for each study, we calculated effective number of cases (N_eff_case) and multiplied it by 2. N_eff_case was derived using the formula N_eff_case = 2 × N_case × N_ctrl/(N_case + N_ctrl), where N_case and N_ctrl is the number of cases (women) and controls (men), respectively. We investigated evidence of heterogeneity using the *I*^2^ statistic ([@DDS304C24]). Genome-wide significance was set to 5 × 10^−8^. We created QQ plots to visualize meta-analysis association results. The power of our study was determined using QUANTO ([@DDS304C25]).

Simulation study {#s4g}
----------------

To exclude the possibility that our null results for autosomal variants are due to either sampling bias or data quality and to examine the probability of having false positives within the power constraints of our study, we sought a theoretical corroboration of our empirical results by conducting association analysis in an 'ideal' unbiased simulated dataset. Simulated genetic data were produced by means of forward-time simulation ([@DDS304C26]--[@DDS304C28]) under a model of a single population with two bottlenecks according to Schaffner *et al*. ([@DDS304C29]) with two exceptions: recent exponential growth of population size (instead of instantaneous changes) and final effective population size of 10^6^ (instead of 10^5^), as this has been shown to be the case for the European population ([@DDS304C30]). Demographic model parameters are given in [Supplementary Material, Table S4](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1). The generation time was assumed to be 25 years, and the mutation rate per site per generation was 1.5 × 10^−8^ ([@DDS304C29]). We applied a fixed sex ratio and a random mating scheme (i.e. parents are randomly selected irrespective of their genotype) validated by different genetic and demographic models ([@DDS304C27]). We set a probability of having a male offspring to 0.5122, which corresponds to a male-to-female ratio of 1.05. Simulations were run for 17 000 generations after which we randomly sampled women and men matching the original study for sample size (women = 61 094; men = 53 769).

We simulated unlinked, neutral, autosomal common variants with initial MAF of 0.02 in the founder population ([@DDS304C27],[@DDS304C31]). The total number of simulated loci was 56 502 900, out of which 2.4% were common (MAF \> 0.05). We performed allele-based chi-squared association tests on the 1 337 699 common loci. This figure matches the estimated number of independent SNPs in HapMap CEU samples of around 1 million ([@DDS304C32]). We additionally performed allele-based Fishers exact association tests on 135 988 low-frequency variants (MAF 0.01--0.05). [Supplementary Material, Figure S4](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1) shows the MAF spectrum for simulated data compared with the 1000 Genomes Project Pilot 3 CEU (2*n* = 60) data.

SUPPLEMENTARY MATERIAL {#s5}
======================

[Supplementary Material is available at *HMG* online.](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1)

###### Supplementary Data
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**WTCCC:** This study makes use of data generated by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed to the generation of the data is available in the [Supplementary Material](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/dds304/-/DC1) and at [www.wtccc.org.uk](www.wtccc.org.uk). Funding for the project was provided by the Wellcome Trust under award 076113.
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**CoLaus**: The authors express their gratitude to the participants in the Lausanne CoLaus study and to the investigators who have contributed to the recruitment. We would like to thank Drs Vincent Mooser and Dawn Waterworth from GlaxoSmithKline for helpful comments and for their continuous support for the CoLaus project. Part of the computation has been performed on the Vital-IT cluster ([www.vital-it.ch](www.vital-it.ch)). We are grateful to Dr. Toby Johnson and Pr. Sven Bergmann for statistical discussions. The CoLaus study was supported by research grants from GlaxoSmithKline; the Faculty of Biology and Medicine of Lausanne, Switzerland; and the Swiss National Science Foundation (grant no:33CSCO-122661). Gérard Waeber and Peter Vollenweider received an unrestricted grant from GSK to build the CoLaus study.
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**CROATIA-Split**: We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including but not limited to The University of Split and Zagreb Medical Schools and Croatian Institute for Public Health. The SNP genotyping for the CROATIA-Split cohort was performed by AROS Applied Biotechnology, Aarhus, Denmark. The CROATIA-Split study is funded by grants from the Medical Research Council (UK) and Republic of Croatia Ministry of Science, Education and Sports research grants to I.R. (108-1080315-0302).

**CROATIA-Vis**: We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including but not limited to The University of Split and Zagreb Medical Schools, Institute for Anthropological Research in Zagreb and Croatian Institute for Public Health. The SNP genotyping for the CROATIA-Vis cohort was performed in the core genotyping laboratory of the Wellcome Trust Clinical Research Facility at the Western General Hospital, Edinburgh, Scotland, UK. The CROATIA-Vis study was funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants (108-1080315-0302).

**ECHRS-Spain**: Spanish Ministry of Science and Innovation grant MTM2008-02457; Fondo de Investigaciones Santarias grants 97/0035-01, 99/0034-01 and 99/0034-02; Hospital Universitario de Albacete; Consejeria de Sanidad; FWO (Fund for Scientific Research) grant G.0402.00; University of Antwerp; the Flemish Health Ministry; Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Public Health Service grant R01 HL62633-01; Consell Interdepartamental de Recerca i Innovació Tecnològica (CIRIT) grant 1999SGR 00241; Red Respira Instituto de Salud Carlos III (ISCIII).

**EGCUT**: EGCUT received financial support from FP7 programs (ENGAGE, OPENGENE), targeted financial support from Estonian Government SF0180142s08, Estonian Research Roadmap through Estonian Ministry of Education and Research, Center of Excellence in Genomics (EXCEGEN) and University of Tartu (SP1GVARENG). The work of K.F. was supported by Estonian Science Foundation grant EstSF ETF9353. We acknowledge EGCUT technical personnel, especially Mr V. Soo and S. Smit. Data analyzes were carried out in part in the High Performance Computing Center of University of Tartu.

**ENGAGE:** This research was supported through funds from The European Community\'s Seventh Framework Programme (FP7/2007-2013), ENGAGE Consortium, grant agreement HEALTH-F4-2007-201413.

**EPIC-Obesity**: The EPIC Norfolk Study is funded by program grants from the Medical Research Council UK and Cancer Research UK.
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